SureTrader Stock Hero Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator binks, Seel
Search This Board:
Last Post: 5/19/2015 3:47:42 PM - Followers: 123 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Why Idera Pharmaceuticals Inc. Shares Vaulted Higher 05/18/2015 03:11:02 PM
IDRA News: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors 05/18/2015 08:30:00 AM
IDRA News: Idera Pharmaceuticals, Inc. Shares Soar On Earnings 05/11/2015 01:39:07 PM
IDRA News: Idera Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update 05/11/2015 07:30:00 AM
IDRA News: Quarterly Report (10-q) 05/11/2015 06:17:37 AM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1769   Sure looks like that is what the "money" Citrati 05/19/15 03:47:42 PM
#1768   just added a bunch on the dip. rivervalley 05/19/15 03:21:26 PM
#1767   Adding Cbdpotential 05/19/15 03:04:32 PM
#1766   3.54 is the key level for a breakout confirmation binchey 05/19/15 08:38:33 AM
#1765   Fingers crossed! Looking great C! TheHound 05/19/15 01:01:01 AM
#1764   Nice day today everyone. Congrats. Citrati 05/19/15 12:41:19 AM
#1763   Ya. I did too. IDRA consistently drops hard Seel 05/18/15 06:14:22 PM
#1762   so glad I added shares here in the rivervalley 05/18/15 02:54:41 PM
#1761   $IDRA recent news/filings stocktrademan 05/18/15 01:55:13 PM
#1760   Understood. Just saying it would be a Beandog 05/18/15 12:04:16 PM
#1759   I added some under $3 and I'm just Randolph Duke 05/18/15 11:52:43 AM
#1758   So the recent downtrend was orchestrated by the Beandog 05/18/15 11:29:49 AM
#1757   Nice bump. Bump and run? Citrati 05/18/15 09:59:33 AM
#1756   48% institutional ownership! binchey 05/16/15 03:51:24 PM
#1755   IDRA is such a tease right now. Should Citrati 05/15/15 06:22:26 PM
#1754   holding shares for a much higher sell price rivervalley 05/14/15 04:08:35 PM
#1753   IDRA sure is trying hard to bottom. Still Citrati 05/14/15 01:15:10 PM
#1752   I sold coz I saw buying hesitation yesterday. PHILTSENG 05/13/15 06:06:33 PM
#1751   View #1 Citrati 05/13/15 04:34:28 PM
#1750   Let's see how it tests 2.60-2.70 level before reentry. PHILTSENG 05/13/15 03:42:00 PM
#1749   Same same here Ebuilder 05/13/15 03:36:29 PM
#1748   Out at 3.03 today. Broad market is at PHILTSENG 05/12/15 04:32:51 PM
#1747   Thanks Citrati. This company has so much going Seel 05/11/15 06:29:16 PM
#1746   great day for IDRA. Look forward to more rivervalley 05/11/15 05:08:27 PM
#1745   Very nice, solid finish to the trading day. Citrati 05/11/15 05:03:37 PM
#1744   This is my third time purchasing IDRA in PHILTSENG 05/11/15 04:40:09 PM
#1743   Good to see you in IDRA binchey 05/11/15 04:25:46 PM
#1742   Squeezed in last Friday. Nice jump! PHILTSENG 05/11/15 04:05:53 PM
#1741   Nice ! Cbdpotential 05/11/15 10:06:20 AM
#1740   Idera Pharmaceuticals Reports First Quarter 2015 Financial Results Citrati 05/11/15 10:04:11 AM
#1739   nice start here, hope this chart is ready rivervalley 05/11/15 10:00:13 AM
#1738   Application of TLR Agonists in Immuno-Oncology Citrati 05/11/15 09:22:50 AM
#1737   IMO-8400 Development Program in Genetically Defined Forms of Citrati 05/11/15 09:21:43 AM
#1736   IDRA...10-Q Citrati 05/11/15 09:19:28 AM
#1735   thank you C! Seel 05/08/15 10:46:10 AM
#1734   Hi Seel, hard to beat a price like Citrati 05/07/15 08:51:28 PM
#1733   yes. I've been here for a while. bought Seel 05/07/15 03:37:39 PM
#1732   I've had IDRA for a long time. Just monkeyfrog 05/07/15 03:26:08 PM
#1731   I bought some more today. IDRA's been boring Seel 05/07/15 03:00:30 PM
#1730   Some interesting new holdings info. monkeyfrog 05/06/15 09:17:33 AM
#1729   decent close, let's see how it goes next week. rivervalley 05/01/15 04:06:03 PM
#1728   Welcome to anyone new or re-entering. Citrati 04/30/15 10:51:26 PM
#1727   Yeah me either. I'm in for a Black sunshine 04/30/15 09:03:27 PM
#1726   Moved into a little IDRA today rarefind 04/30/15 03:54:30 PM
#1725   I said 50% retrace to 2.75 3 weeks etradeedge 04/30/15 02:27:31 PM
#1724   Don't forget the IBB sector smash. 333.78 Citrati 04/30/15 02:23:18 PM
#1723   Most biotechs are doing horrible. Poor earnings...Celladon Black sunshine 04/30/15 01:40:43 PM
#1722   Filled the gap from 2.82-2.85 maybe now it Citrati 04/30/15 09:33:02 AM
#1721   I've been playing gaps lately, Placed an order stocking4ms 04/29/15 06:00:45 PM
#1720   Waiting for it to dip to $2.50 range- Randolph Duke 04/29/15 03:46:15 PM
PostSubject